Definium Therapeutics, Inc. (DFTX)

DFTX Biotech / Pharma

BiotechSign Signal Grade

F
Signal Grade
26.3/100 composite signal score

Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.

Publications
10
Dilution Risk
30
Clinical Activity
25
Short Interest
30

Pipeline Overview

Therapeutic Focus
Biotech / Pharmasrc

Clinical Trial Activity

1
Clinical Trial
(ClinicalTrials.gov aggregate)
2
PubMed Publications
0
Catalyst Records

ClinicalTrials.gov aggregate as of 2026-11-16. ClinicalTrials.gov

Dilution Risk

MEDIUM DILUTION RISK
123.2 months
Cash Runway Estimate
30/100
Dilution Score
15Warrant Risk
15Convertible Risk
60Offering Ability

Dilution score: 30/100 (MEDIUM), 123.2 months cash

Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score

Short Interest

8.89%
Float Shorted
5.8
Days to Cover
MODERATE
Squeeze Risk
-4.3%
SI Change
STABLE
Trend
9,613,993
Shares Short

Short interest: 8.89% of float, squeeze risk: MODERATE

FINRA short sale data. FINRA short interest

Evidence and freshness

Record counts and statuses were computed on 2026-11-21. A source date shows only when we store one; otherwise it says “not recorded”. Spot an error? Report a data error.

PDUFA / FDA dates 0 No records
No upcoming FDA decision date found in the company's SEC filings
SEC 8-K filing
Clinical trials 1 Current
Updated within the last 14 days
ClinicalTrials.gov
source date not recorded · ingested Nov 16, 2026
Insider activity 0 Unavailable
No record on file; source last refreshed Nov 21, 2026
SEC EDGAR Form 4
Dilution risk 1 Derived
Derived score calculated from SEC data, not a raw record
DilutionWatch score (derived from SEC filings)
source date not recorded · ingested Nov 21, 2026
Short interest 1 Current
Updated within the last 21 days
FINRA short interest
source date not recorded · ingested Nov 21, 2026
Publications 2 Current
Updated within the last 30 days
PubMed
source date not recorded · ingested Nov 20, 2026

How the signal grade is calculated

The score (0–100) is a weighted average of the source-backed signals we hold for a company: FDA decision date 35%, clinical trials 25%, insider buying 15%, dilution risk 8%, signal convergence 7%, short interest 3%, and 0.5–2% each for smaller signals. A signal we have no record for drops out and the others share its weight. Grades: A ≥ 80, B ≥ 65, C ≥ 50, D ≥ 35, F below 35.

What drives this company's 26.3/100 (grade F):

  • Clinical trials: signal score 0.25, weight used 68%, 17.1 points
  • Dilution risk: signal score 0.30, weight used 22%, 6.6 points
  • Short interest: signal score 0.30, weight used 8%, 2.5 points
  • Publications: signal score 0.10, weight used 1%, 0.1 points

Freshness: PDUFA dates that have passed score 0; clinical-trial records older than 90 days are ignored; dilution scores older than 7 days are withdrawn; scores are recalculated daily. Derived signals: the overall score and grade, the dilution-risk score (DilutionWatch, calculated from SEC filings) and signal convergence. The grade is not a forecast of FDA approval, a trial result or a stock move, and not investment advice.

Recent News & SEC Filings

Headlines from public sources. BiotechSign does not endorse or verify linked content.

Recent Publications

Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Definium Therapeutics, Inc..

Full DFTX Dashboard Sign Up Free

Primary Sources

This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.